tetano
Editor, Senior Moderator
Vet Res. 2015 Apr 16;46(1):42. doi: 10.1186/s13567-015-0174-3.
[h=1]Efficient strategy for constructing duck enteritis virus-based live attenuated vaccine against homologous and heterologous H5N1 avian influenza virus and duck enteritis virus infection.[/h] Zou Z[SUP]1,[/SUP][SUP]2[/SUP], Hu Y[SUP]3,[/SUP][SUP]4[/SUP], Liu Z[SUP]5,[/SUP][SUP]6,[/SUP][SUP]7[/SUP], Zhong W[SUP]8,[/SUP][SUP]9[/SUP], Cao H[SUP]10,[/SUP][SUP]11[/SUP], Chen H[SUP]12,[/SUP][SUP]13[/SUP], Jin M[SUP]14,[/SUP][SUP]15[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Duck is susceptible to many pathogens, such as duck hepatitis virus, duck enteritis virus (DEV), duck tembusu virus, H5N1 highly pathogenic avian influenza virus (HPAIV) in particular. With the significant role of duck in the evolution of H5N1 HPAIV, control and eradication of H5N1 HPAIV in duck through vaccine immunization is considered an effective method in minimizing the threat of a pandemic outbreak. Consequently, a practical strategy to construct a vaccine against these pathogens should be determined. In this study, the DEV was examined as a candidate vaccine vector to deliver the hemagglutinin (HA) gene of H5N1, and its potential as a polyvalent vaccine was evaluated. A modified mini-F vector was inserted into the gB and UL26 gene junction of the attenuated DEV vaccine strain C-KCE genome to generate an infectious bacterial artificial chromosome (BAC) of C-KCE (vBAC-C-KCE). The HA gene of A/duck/Hubei/xn/2007 (H5N1) was inserted into the C-KCE genome via the mating-assisted genetically integrated cloning (MAGIC) to generate the recombinant vector pBAC-C-KCE-HA. A bivalent vaccine C-KCE-HA was developed by eliminating the BAC backbone. Ducks immunized with C-KCE-HA induced both the cross-reactive antibodies and T cell response against H5. Moreover, C-KCE-HA-immunized ducks provided rapid and long-lasting protection against homologous and heterologous HPAIV H5N1 and DEV clinical signs, death, and primary viral replication. In conclusion, our BAC-C-KCE is a promising platform for developing a polyvalent live attenuated vaccine.
PMID: 25889564 [PubMed - in process] PMCID: PMC4397706
[h=1]Efficient strategy for constructing duck enteritis virus-based live attenuated vaccine against homologous and heterologous H5N1 avian influenza virus and duck enteritis virus infection.[/h] Zou Z[SUP]1,[/SUP][SUP]2[/SUP], Hu Y[SUP]3,[/SUP][SUP]4[/SUP], Liu Z[SUP]5,[/SUP][SUP]6,[/SUP][SUP]7[/SUP], Zhong W[SUP]8,[/SUP][SUP]9[/SUP], Cao H[SUP]10,[/SUP][SUP]11[/SUP], Chen H[SUP]12,[/SUP][SUP]13[/SUP], Jin M[SUP]14,[/SUP][SUP]15[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Duck is susceptible to many pathogens, such as duck hepatitis virus, duck enteritis virus (DEV), duck tembusu virus, H5N1 highly pathogenic avian influenza virus (HPAIV) in particular. With the significant role of duck in the evolution of H5N1 HPAIV, control and eradication of H5N1 HPAIV in duck through vaccine immunization is considered an effective method in minimizing the threat of a pandemic outbreak. Consequently, a practical strategy to construct a vaccine against these pathogens should be determined. In this study, the DEV was examined as a candidate vaccine vector to deliver the hemagglutinin (HA) gene of H5N1, and its potential as a polyvalent vaccine was evaluated. A modified mini-F vector was inserted into the gB and UL26 gene junction of the attenuated DEV vaccine strain C-KCE genome to generate an infectious bacterial artificial chromosome (BAC) of C-KCE (vBAC-C-KCE). The HA gene of A/duck/Hubei/xn/2007 (H5N1) was inserted into the C-KCE genome via the mating-assisted genetically integrated cloning (MAGIC) to generate the recombinant vector pBAC-C-KCE-HA. A bivalent vaccine C-KCE-HA was developed by eliminating the BAC backbone. Ducks immunized with C-KCE-HA induced both the cross-reactive antibodies and T cell response against H5. Moreover, C-KCE-HA-immunized ducks provided rapid and long-lasting protection against homologous and heterologous HPAIV H5N1 and DEV clinical signs, death, and primary viral replication. In conclusion, our BAC-C-KCE is a promising platform for developing a polyvalent live attenuated vaccine.
PMID: 25889564 [PubMed - in process] PMCID: PMC4397706